Inhibition of nuclear factor κb transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells

Anti-Cancer Drugs

Volumn 27, Issue 4, 2016, Pages 286-299

  Dong, Xinjun ^a   Liu, Feiyan ^a   Li, Mianli ^a  

^a Affiliated Hospital of Binzhou Medical University   (China)

Author keywords

Apoptosis; Cisplatin; Hepatocellular carcinoma; Nuclear factor B; Oridonin

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ORIDONIN; ANTINEOPLASTIC AGENT; KAURANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA BINDING; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; LIVER NEOPLASMS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TRANSCRIPTION INITIATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CISPLATIN; DITERPENES, KAURANE; DRUG SYNERGISM; HEP G2 CELLS; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; TRANSCRIPTIONAL ACTIVATION;

EID: 84951309834     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000329     Document Type: Article

References (38)

1. Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: new advances and challenges. World J Hepatol 2015; 7:787-798.
2. Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol 2014; 20:4151-4159.
3. Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 2012; 32:1379-1386.
4. Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012; 1:62-70.
5. He G, Karin M. NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res 2011; 21:159-168.
6. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005; 25:212-225.
7. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 2007; 28:365-386.
8. Zhou G, Kuo MT. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 1997; 272:15174-15183.
9. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-5929.
10. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5:412-417.
11. Muriel P. NF-kappaB in liver diseases: a target for drug therapy. J Appl Toxicol 2009; 29:91-100.
12. Li CY,Wang EQ, Cheng Y, Bao JK. Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 2011; 43:701-704.
13. Liu Z, Ouyang L, Peng H, Zhang WZ. Oridonin: targeting programmed cell death pathways as an anti-tumour agent. Cell Prolif 2012; 45:499-507.
14. Zhao Z, Chen Y. Oridonin a promising antitumor natural product in the chemotherapy of hematological malignancies. Curr Pharm Biotechnol 2014; 15:1083-1092.
15. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005; 4:578-586.
16. Zheng X, Lv J, Shen Q, Chen Y, Zhou Q, ZhangW, et al. Synergistic effect of pyrrolidine dithiocarbamate and cisplatin in human cervical carcinoma. Reprod Sci 2014; 21:1319-1325.
17. Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin 2004; 25:146-147.
18. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5:85-91.
19. Kano Y, Ohnuma T, Okano T, Holland JF. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 1988; 48:351-356.
20. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992; 50:604-610.
21. Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One 2013; 8:e58037.
22. Wu HY, Tomizawa K, Oda Y, Wei FY, Lu YF, Matsushita M, et al. Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem 2004; 279:4929-4940.
23. Vogel CF, Li W, Sciullo E, Newman J, Hammock B, Reader JR, et al. Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. Am J Pathol 2007; 171:1538-1548.
24. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 2008; 3:1101-1108.
25. Mahawar M, Atianand MK, Dotson RJ, Mora V, Rabadi SM, Metzger DW, et al. Identification of a novel Francisella tularensis factor required for intramacrophage survival and subversion of innate immune response. J Biol Chem 2012; 287:25216-25229.
26. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16:225-260.
27. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001; 107:3-6.
28. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470:M55-M62.
29. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107:241-246.
30. Wu K, Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 2009; 29:241-254.
31. Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target. J Cell Biochem 2004; 92:646-650.
32. Wang H, Cho CH. Effect of NF-kappaB signaling on apoptosis in chronic inflammation-associated carcinogenesis. Curr Cancer Drug Targets 2010; 10:593-599.
33. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, et al. NF-kappa B2/p100 induces bcl-2 expression. Leukemia 2003; 17:1349-1356.
34. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol Cell Biol 2000; 20:2687-2695.
35. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006; 25:6717-6730.
36. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 2008; 107:370-379.
37. Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, et al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 2013; 8:e81162.
38. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 2008; 28:337-344.